The m⁶A Epitranscriptome: A Regulatory Nexus Linking Cellular Senescence and Oncogenesis.

Yao Xu, Xin Zhou, Xiaoling Su, Wenxi Xie, Zhijie Huang, Shan Yu, Jinghua Tan, Jun He, Ji Zhang

The Affiliated Nanhua Hospital, Department of Clinical Laboratory, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.The Affiliated Nanhua Hospital, Department of Clinical Laboratory, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. · pubmed

Paper

Abstract

N⁶-methyladenosine (m⁶A) orchestrates RNA fate decisions through a dynamic interplay of writers, erasers, and readers, modulating splicing, stability, and translation. This review unveils how m⁶A fine-tunes senescence-associated pathways (p53/p21, p16-RB) with cancer-context-dependent duality-either as a tumor suppressor or promoter of progression/resistance. Leveraging single-cell and spatial omics, we dissect m⁶A's spatiotemporal heterogeneity in tumor-immune ecosystems. We consolidate diagnostic/prognostic biomarker advances and critically evaluate emerging therapeutics (small-molecule inhibitors, allosteric modulators, nanodelivery systems), addressing clinical barriers like selectivity and safety. Finally, we propose precision strategies targeting m⁶A-senescence networks for combined anti-cancer/anti-aging interventions.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that m⁶A modifications regulate cellular senescence pathways, influencing cancer progression and potential anti-aging strategies. The focus on m⁶A's role in senescence and its implications for therapeutic interventions targeting aging processes makes it relevant to longevity research.

Author of this paper? Send a correction.